市場調査レポート

商品コード

1488618

ベタメタゾンリン酸エステルナトリウム市場：形態別、純度別、適応疾患別、地域別、機会、予測、2017年～2031年

Betamethasone Sodium Phosphate Market Assessment, By Form, By Purity, By Disease Indication, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年06月05日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 233 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 679,320円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 860,472円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,237,872円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.96円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のベタメタゾンリン酸エステルナトリウムの市場規模は、予測期間の2024年～2031年に6.51%のCAGRで拡大し、2023年の6億720万米ドルから2031年には10億567万米ドルに成長すると予測されています。市場の成長は、関節炎とアレルギーの有病率の上昇に起因しています。

世界のベタメタゾンリン酸エステルナトリウム市場の需要は、関節や腱の問題、関節炎、皮膚の問題など、さまざまな健康状態の有病率の上昇により増加しています。ベタメタゾンリン酸エステルナトリウムは、このような症状を治療するための注射剤として一般的に使用されています。ベタメタゾンはNF-Kappa Bのような炎症性転写因子とともに脱皮および好中球のアポトーシスを阻害し、ホスホリパーゼA2を阻害してアラキドン酸誘導体の形成を減少させます。ベタメタゾンなどのコルチコステロイドは、ゲノム経路と非ゲノム経路の両方を通して作用します。非ゲノム経路は、既存のセカンドメッセンジャーや膜結合レセプターを利用することにより、単球活性、T細胞、血小板を調節し、より速い反応を引き起こすことができます。一方、ゲノム経路は反応が遅く、グルココルチコイドがグルココルチコイド受容体を活性化し、チロシンアミノトランスフェラーゼ（TAT）、IL-1受容体拮抗薬、ホスホエノールピルビン酸カルボキシキナーゼ（PEPCK）などの様々な抗炎症遺伝子の転写を可能にする下流効果を開始した後にのみ起こります。

様々なタイプの関節炎患者の増加は、市場に有利な成長機会をもたらしています。例えば、米国疾病予防管理センターは、2019年～2021年に米国の成人（18歳から44歳まで）の約5.4％が関節炎を報告していると推定しています。関節炎の症例数の増加は、急性痛風性関節炎、関節リウマチ、急性非特異的腱鞘炎、変形性関節症の滑膜炎、上顆炎、急性・亜急性滑液包炎の患者に、ベタメタゾン酢酸エステル注射用懸濁液と組み合わせて短期間関節内に投与されるため、ベタメタゾンナトリウムリン酸塩の必要性を押し上げています。そのため、ベタメタゾンリン酸エステルナトリウムの需要が高まり、市場の拡大が加速しています。

当レポートでは、世界のベタメタゾンリン酸エステルナトリウム市場について調査し、市場の概要とともに、形態別、純度別、適応疾患別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 2.Global Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 3.Global Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 4.Global Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 5.Global Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 6.Global Betamethasone Sodium Phosphate Market Share (%), By Region, 2017-2031F
Figure 7.North America Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 8.North America Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 9.North America Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 10.North America Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 11.North America Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 12.North America Betamethasone Sodium Phosphate Market Share (%), By Country, 2017-2031F
Figure 13.United States Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 14.United States Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 15.United States Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 16.United States Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 17.United States Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 18.Canada Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 19.Canada Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 20.Canada Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 21.Canada Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 22.Canada Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 23.Mexico Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 24.Mexico Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 25.Mexico Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 26.Mexico Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 27.Mexico Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 28.Europe Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 29.Europe Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 30.Europe Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 31.Europe Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 32.Europe Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 33.Europe Betamethasone Sodium Phosphate Market Share (%), By Country, 2017-2031F
Figure 34.Germany Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 35.Germany Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 36.Germany Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 37.Germany Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 38.Germany Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 39.France Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 40.France Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 41.France Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 42.France Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 43.France Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 44.Italy Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 45.Italy Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 46.Italy Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 47.Italy Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 48.Italy Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 49.United Kingdom Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 50.United Kingdom Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 51.United Kingdom Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 52.United Kingdom Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 53.United Kingdom Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 54.Russia Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 55.Russia Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 56.Russia Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 57.Russia Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 58.Russia Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 59.Netherlands Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 60.Netherlands Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 61.Netherlands Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 62.Netherlands Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 63.Netherlands Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 64.Spain Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 65.Spain Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 66.Spain Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 67.Spain Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 68.Spain Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 69.Turkey Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 70.Turkey Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 71.Turkey Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 72.Turkey Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 73.Turkey Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 74.Poland Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 75.Poland Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 76.Poland Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 77.Poland Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 78.Poland Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 79.South America Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 80.South America Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 81.South America Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 82.South America Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 83.South America Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 84.South America Betamethasone Sodium Phosphate Market Share (%), By Country, 2017-2031F
Figure 85.Brazil Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 86.Brazil Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 87.Brazil Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 88.Brazil Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 89.Brazil Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 90.Argentina Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 91.Argentina Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 92.Argentina Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 93.Argentina Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 94.Argentina Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 95.Asia-Pacific Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 96.Asia-Pacific Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 97.Asia-Pacific Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 98.Asia-Pacific Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 99.Asia-Pacific Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 100.Asia-Pacific Betamethasone Sodium Phosphate Market Share (%), By Country, 2017-2031F
Figure 101.India Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 102.India Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 103.India Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 104.India Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 105.India Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 106.China Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 107.China Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 108.China Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 109.China Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 110.China Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 111.Japan Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 112.Japan Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 113.Japan Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 114.Japan Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 115.Japan Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 116.Australia Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 117.Australia Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 118.Australia Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 119.Australia Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 120.Australia Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 121.Vietnam Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 122.Vietnam Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 123.Vietnam Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 124.Vietnam Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 125.Vietnam Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 126.South Korea Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 127.South Korea Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 128.South Korea Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 129.South Korea Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 130.South Korea Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 131.Indonesia Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 132.Indonesia Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 133.Indonesia Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 134.Indonesia Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 135.Indonesia Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 136.Philippines Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 137.Philippines Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 138.Philippines Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 139.Philippines Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 140.Philippines Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 141.Middle East & Africa Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 142.Middle East & Africa Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 143.Middle East & Africa Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 144.Middle East & Africa Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 145.Middle East & Africa Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 146.Middle East & Africa Betamethasone Sodium Phosphate Market Share (%), By Country, 2017-2031F
Figure 147.Saudi Arabia Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 148.Saudi Arabia Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 149.Saudi Arabia Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 150.Saudi Arabia Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 151.Saudi Arabia Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 152.UAE Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 153.UAE Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 154.UAE Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 155.UAE Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 156.UAE Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 157.South Africa Betamethasone Sodium Phosphate Market, By Value, in USD Million, 2017-2031F
Figure 158.South Africa Betamethasone Sodium Phosphate Market, By Volume, in Kilotons, 2017-2031F
Figure 159.South Africa Betamethasone Sodium Phosphate Market Share (%), By Form, 2017-2031F
Figure 160.South Africa Betamethasone Sodium Phosphate Market Share (%), By Purity, 2017-2031F
Figure 161.South Africa Betamethasone Sodium Phosphate Market Share (%), By Disease Indication, 2017-2031F
Figure 162.By Form Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 163.By Purity Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 164.By Disease Indication Map-Market Size (USD Million) & Growth Rate (%), 2023
Figure 165.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023

Product Code: MX11407

The global betamethasone sodium phosphate market is projected to witness a CAGR of 6.51% during the forecast period 2024-2031, growing from USD 607.2 million in 2023 to USD 1005.67 million in 2031F. The market's growth is attributed to the increasing prevalence of arthritis and allergies.

The global betamethasone sodium phosphate market demand is rising owing to the increasing prevalence of various health conditions, including joint and tendon problems, arthritis, and skin problems. Betamethasone sodium phosphate is commonly used for injections to treat such conditions. It inhibits demargination and neutrophil apoptosis along with inflammatory transcription factors such as NF-Kappa B. It inhibits phospholipase A2, resulting in reduced formation of arachidonic acid derivatives. Corticosteroids such as betamethasone can act through both genomic and non-genomic pathways. The nongenomic pathways can elicit a faster response by modulating monocyte activity, T-cells, and platelets through the utilization of existing second messengers and membrane-bound receptors. Whereas the genomic pathways are slower and occur only after the glucocorticoids activate the glucocorticoid receptors, initiating the downstream effects that allows the transcription of various anti-inflammatory genes such as tyrosine amino transferase (TAT), IL-1-receptor antagonist, and phosphoenolpyruvate carboxykinase (PEPCK).

The rising cases of different types of arthritis are providing lucrative growth opportunities to the market. For instance, the Centre for Disease Control and Prevention estimates that approximately 5.4% of the adults (from age 18 to 44 years) in the United States have reported arthritis from 2019-2021. The increase in number of cases of arthritis is boosting the requirement for betamethasone sodium phosphate as it is administered intra-articularly in combination with betamethasone acetate injectable suspension for short term in patients with acute gouty arthritis, rheumatoid arthritis, acute nonspecific tenosynovitis, synovitis of osteoarthritis, epicondylitis, and acute and subacute bursitis. Thus, propelling the demand for betamethasone sodium phosphate and augmenting the expansion of the market.

Rising Requirement for Betamethasone Sodium Phosphate Injections Boosts Market Growth

Betamethasone sodium phosphate injections are steroid drugs used for treating various conditions associated with inflammation, including Crohn's disease, arthritis, ulcerative colitis, allergies, and asthma. The increasing prevalence of asthma is propelling the requirement for these injections. For instance, the American College of Allergy, Asthma and Immunology estimates that 7.7% of Americans (24.9 million individuals) suffered from asthma 2023. Of these, approximately 4.6 million are children and 20.2 million are adults. Injections are used for treating different types of disorders, including issues related to the nervous system, blood, liver, skin, and eye. The active pharmaceutical ingredient used in these injections is betamethasone sodium phosphate. Thus, bolstering the demand for the product and aiding the market expansion.

These injections are generally administered when the patient cannot consume the oral form of the medication. They are given to pregnant women who are at risk of delivering preterm to reduce the risk of development of breathing problems in the fetus. Furthermore, betamethasone is a moderately potent glucocorticoid steroid with immunosuppressive and anti-inflammatory properties. Unlike other drugs that have these properties, betamethasone is not responsible for causing the retention of water. It is sometimes used in conjunction with antihistamine to reduce irritation. Thus augmenting the requirement for these injections and boosting the global betamethasone sodium phosphate market demand.

Rising Cases of Rheumatoid Arthritis Facilitate Market Expansion

The rise in the number of cases of rheumatoid arthritis is positively influencing the expansion of the market. The Center for Disease Control and Prevention estimated that approximately one in four or 26% of adults aged 45-64 have arthritis. The increase supports the expansion of the market as betamethasone sodium phosphate finds applications in various medications that are used to treat inflammation associated with rheumatoid arthritis. Betamethasone sodium phosphate encapsulated in poly (D, L- glycolic/ lactic acid) nanoparticles works effectively in the case of rheumatoid arthritis. They aid in decreasing soft tissue swelling and paw inflammation and relieve inflammatory response by decreasing the number of inflammatory cells in the joints. Thus, this propels the requirement for betamethasone sodium phosphate to manage the inflammation caused by rheumatoid arthritis and augment the market's growth.

North America Accounts for a Significant Share of the Market

The strong presence of various leading market players, the rising requirement for betamethasone sodium phosphate, owing to the increasing prevalence of various health conditions, such as arthritis and allergic disorders, and rising investments by major research institutions towards research activities are the factors contributing towards the dominance of North America in global betamethasone sodium phosphate market. For instance, the OrthoCarolina Research Institute, Inc., United States, is conducting an interventional study for determining if the corticosteroid injection (betamethasone) modifies the course of De Quervain's Tenosynovitis in comparison to a toradol injection (Ketorolac). The study is estimated to conclude in December 2024. Rise in number of such studies will augment the demand for betamethasone sodium phosphate as they will aid researchers and scientists in determining the safety and efficacy of the medications derived from the chemical. Moreover, the increasing prevalence of asthma in various countries in North America is further boosting the requirement for betamethasone sodium phosphate.

Rising Demand for Solid Form of Betamethasone Sodium Phosphate Boosts Market Size

The increasing requirement for solid betamethasone sodium phosphate can be attributed to various product benefits, including ease of handling. The cost efficiency offered by the product due to easy transportation and distribution further augment the popularity of solid form of betamethasone sodium phosphate. Additionally, they are preferred by the pharmaceutical industry for formulating injections and tablets. The pharma industry's rapid expansion due to the increasing prevalence of various diseases is further propelling the demand for betamethasone sodium phosphate. The European Federation of Pharmaceutical Industries and Association estimates that in 2021, Europe accounted for 23.4% of the world pharmaceutical sales whereas North America accounted for 49.1%. Thus, it supports the expansion of the pharmaceutical industry in various regions and boosts the demand for various pharma products, including those that contain betamethasone sodium phosphate, augmenting the expansion of the market.

Betamethasone Sodium Phosphate with More than 99% Purity Dominates Market Share

The rising requirement for betamethasone sodium phosphate with more than 99% purity can be attributed to the growing prevalence of various conditions that cause inflammation. Betamethasone sodium phosphate binds to the intracellular glucocorticoid receptors and later binds to the DNA to modify gene expression. The disodium salt of 21-phosphate ester of betamethasone has anti-inflammatory, metabolic, and immunosuppressive actions. It inhibits the synthesis of various inflammatory mediators and induces the synthesis of anti-inflammatory proteins. As a result, an overall reduction in autoimmune reactions and chronic inflammation is witnessed.

Due to these properties of betamethasone sodium phosphate, the demand for the chemical with more than 99% purity is increasing from the pharmaceutical sector, bolstering the segment's expansion. Additionally, the rapid expansion of the pharmaceutical industry in various regions across the globe is further providing lucrative growth opportunities to the market. For instance, Invest India estimates that the pharmaceutical industry in the country will reach a value of USD 130 billion by 2030. The growth of the pharma industry will propel the requirement for betamethasone sodium phosphate with more than 99% purity and provide lucrative growth opportunities to the market.

Future Market Scenario (2024 - 2031F)

The rising efforts by various leading players of global betamethasone sodium phosphate market and research institutions are expected to evaluate the effects of betamethasone sodium phosphate for treating various conditions will provide lucrative growth opportunities to the market. For instance, Thammasat University, Thailand, is conducting an interventional study to compare the efficacy of intra-articular corticosteroid injection of Triamcinolone acetonide and Betamethasone (Diprospan) for treating knee osteoarthritis. The eligibility criteria for patient selection includes symptomatic primary knee osteoarthritis. The study is expected to conclude in June 2024. Increasing investments towards such studies will boost the demand for betamethasone sodium phosphate over the forecast period. Furthermore, the expansion of the market will also be supported by the increase in cases of arthritis in various regions across the globe and rising utilization of betamethasone sodium phosphate for treating inflammation and severe allergies, among others.

Key Players Landscape and Outlook

The increase in mergers, acquisitions, and collaborations between the leading API manufacturers is positively influencing the expansion of global betamethasone sodium phosphate market. Various leading players in the market are actively investing in enhancing their manufacturing facilities owing to the rising requirement for betamethasone sodium phosphate due to the increasing prevalence of arthritis and allergies, among others.

1.Research Methodology

2.Project Scope and Definitions

3.Executive Summary

4.Voice of Customer

4.1.Market Awareness and Product Information
4.2.Brand Awareness and Loyalty
4.3.Factors Considered in Purchase Decision
- 4.3.1.Brand Name
- 4.3.2.Quality
- 4.3.3.Quantity
- 4.3.4.Price
- 4.3.5.Product Specification
- 4.3.6.Form Specification
- 4.3.7.Shelf Life
- 4.3.8.Availability of Product
4.4.Frequency of Purchase
4.5.Medium of Purchas

5.Global Betamethasone Sodium Phosphate Market Outlook, 2017-2031F

5.1.Market Size & Forecast
- 5.1.1.By Value
- 5.1.2.By Volume
5.2.By Form
- 5.2.1.Solid
- 5.2.2.Liquid
5.3.By Purity
- 5.3.1.Less than 98%
- 5.3.2.98% to 99%
- 5.3.3.More than 99%
5.4.By Disease Indication
- 5.4.1.Allergies
- 5.4.2.Arthritis
- 5.4.3.Lupus
- 5.4.4.Ulcerative Colitis
- 5.4.5.Asthma
- 5.4.6.Others
5.5.By Region
- 5.5.1.North America
- 5.5.2.South America
- 5.5.3.Europe
- 5.5.4.Asia-Pacific
- 5.5.5.Middle East and Africa
5.6.By Company Market Share (%), 2023

6.Global Betamethasone Sodium Phosphate Market Outlook, By Region, 2017-2031F

6.1.North America*
- 6.1.1.Market Size & Forecast
  - 6.1.1.1.By Value
  - 6.1.1.2.By Volume
- 6.1.2.By Form
  - 6.1.2.1.Solid
  - 6.1.2.2.Liquid
- 6.1.3.By Purity
  - 6.1.3.1.Less than 98%
  - 6.1.3.2.98% to 99%
  - 6.1.3.3.More than 99%
- 6.1.4.By Disease Indication
  - 6.1.4.1.Allergies
  - 6.1.4.2.Arthritis
  - 6.1.4.3.Lupus
  - 6.1.4.4.Ulcerative Colitis
  - 6.1.4.5.Asthma
  - 6.1.4.6.Others
- 6.1.5.United States*
  - 6.1.5.1.Market Size & Forecast
    - 6.1.5.1.1.By Value
    - 6.1.5.1.2.By Volume
  - 6.1.5.2.By Form
    - 6.1.5.2.1.Solid
    - 6.1.5.2.2.Liquid
  - 6.1.5.3.By Purity
    - 6.1.5.3.1.Less than 98%
    - 6.1.5.3.2.98% to 99%
    - 6.1.5.3.3.More than 99%
  - 6.1.5.4.By Disease Indication
    - 6.1.5.4.1.Allergies
    - 6.1.5.4.2.Arthritis
    - 6.1.5.4.3.Lupus
    - 6.1.5.4.4.Ulcerative Colitis
    - 6.1.5.4.5.Asthma
    - 6.1.5.4.6.Others
- 6.1.6.Canada
- 6.1.7.Mexico

All segments will be provided for all regions and countries covered

6.2.Europe
- 6.2.1.Germany
- 6.2.2.France
- 6.2.3.Italy
- 6.2.4.United Kingdom
- 6.2.5.Russia
- 6.2.6.Netherlands
- 6.2.7.Spain
- 6.2.8.Turkey
- 6.2.9.Poland
6.3.Asia-Pacific
- 6.3.1.India
- 6.3.2.China
- 6.3.3.Japan
- 6.3.4.Australia
- 6.3.5.Vietnam
- 6.3.6.South Korea
- 6.3.7.Indonesia
- 6.3.8.Philippines
6.4.South America
- 6.4.1.Brazil
- 6.4.2.Argentina
6.5.Middle East and Africa
- 6.5.1.Saudi Arabia
- 6.5.2.UAE
- 6.5.3.South Africa

7.Supply Side Analysis

7.1.Capacity, By Company
7.2.Production, By Company
7.3.Operating Efficiency, By Company
7.4.Key Plant Locations (Up to 25)

8.Market Mapping, 2023

8.1.By Form
8.2.By Purity
8.3.By Disease Indication
8.4.By Region

9.Macro Environment and Industry Structure

9.1.Supply Demand Analysis
9.2.Import Export Analysis
9.3.Value Chain Analysis
9.4.PESTEL Analysis
- 9.4.1.Political Factors
- 9.4.2.Economic System
- 9.4.3.Social Implications
- 9.4.4.Technological Advancements
- 9.4.5.Environmental Impacts
- 9.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
9.5.Porter's Five Forces Analysis
- 9.5.1.Supplier Power
- 9.5.2.Buyer Power
- 9.5.3.Substitution Threat
- 9.5.4.Threat from New Entrant
- 9.5.5.Competitive Rivalry

10.Market Dynamics

10.1.Growth Drivers
10.2.Growth Inhibitors (Challenges and Restraints)

11.Key Players Landscape

11.1.Competition Matrix of Top Five Market Leaders
11.2.Market Revenue Analysis of Top Five Market Leaders (by Value, 2023)
11.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4.SWOT Analysis (For Five Market Players)
11.5.Patent Analysis (If Applicable)

12.Pricing Analysis

13.Case Studies

14.Key Players Outlook

14.1.Fengchen Group Co.,Ltd
- 14.1.1.Company Details
- 14.1.2.Key Management Personnel
- 14.1.3.Products and Services
- 14.1.4.Financials (As reported)
- 14.1.5.Key Market Focus and Geographical Presence
- 14.1.6.Recent Developments
14.2.Symbiotec Pharmalab Pvt. Ltd.
14.3.Anuh Pharma Ltd.
14.4.Curia Global, Inc.
14.5.Envee Drugs Pvt. Ltd.
14.6.Newchem (Zhejiang Xianju Pharmaceutical Co., Ltd.)
14.7.SM Biomed Sdn. Bhd.
14.8.Prachem Laboratories Pvt. Ltd.
14.9.Merck KGaA (Sigma-Aldrich)
14.10.Midas Pharma GmbH

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

ベタメタゾンリン酸エステルナトリウム市場：形態別、純度別、適応疾患別、地域別、機会、予測、2017年～2031年

Betamethasone Sodium Phosphate Market Assessment, By Form, By Purity, By Disease Indication, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章顧客の声

第5章ベタメタゾンリン酸エステルナトリウムの世界市場の見通し、2017年～2031年

第6章世界のベタメタゾンリン酸エステルナトリウム市場の見通し、地域別、2017年～2031年

第7章供給側分析

第8章市場マッピング、2023年

第9章マクロ環境と産業構造

第10章市場力学

第11章主要参入企業の情勢

第12章価格分析

第13章ケーススタディ

第14章主要参入企業の見通し

第15章戦略的提言

第16章お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope and Definitions

3.Executive Summary

4.Voice of Customer

5.Global Betamethasone Sodium Phosphate Market Outlook, 2017-2031F

6.Global Betamethasone Sodium Phosphate Market Outlook, By Region, 2017-2031F

7.Supply Side Analysis

8.Market Mapping, 2023

9.Macro Environment and Industry Structure

10.Market Dynamics

11.Key Players Landscape

12.Pricing Analysis

13.Case Studies

14.Key Players Outlook

15.Strategic Recommendations

16.About Us and Disclaimer

ベタメタゾンリン酸エステルナトリウム市場：形態別、純度別、適応疾患別、地域別、機会、予測、2017年～2031年

Betamethasone Sodium Phosphate Market Assessment, By Form, By Purity, By Disease Indication, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 ベタメタゾンリン酸エステルナトリウムの世界市場の見通し、2017年～2031年

第6章 世界のベタメタゾンリン酸エステルナトリウム市場の見通し、地域別、2017年～2031年

第7章 供給側分析

第8章 市場マッピング、2023年

第9章 マクロ環境と産業構造

第10章 市場力学

第11章 主要参入企業の情勢

第12章 価格分析

第13章 ケーススタディ

第14章 主要参入企業の見通し

第15章 戦略的提言

第16章 お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope and Definitions

3.Executive Summary

4.Voice of Customer

5.Global Betamethasone Sodium Phosphate Market Outlook, 2017-2031F

6.Global Betamethasone Sodium Phosphate Market Outlook, By Region, 2017-2031F

7.Supply Side Analysis

8.Market Mapping, 2023

9.Macro Environment and Industry Structure

10.Market Dynamics

11.Key Players Landscape

12.Pricing Analysis

13.Case Studies

14.Key Players Outlook

15.Strategic Recommendations

16.About Us and Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章顧客の声

第5章ベタメタゾンリン酸エステルナトリウムの世界市場の見通し、2017年～2031年

第6章世界のベタメタゾンリン酸エステルナトリウム市場の見通し、地域別、2017年～2031年

第7章供給側分析

第8章市場マッピング、2023年

第9章マクロ環境と産業構造

第10章市場力学

第11章主要参入企業の情勢

第12章価格分析

第13章ケーススタディ

第14章主要参入企業の見通し

第15章戦略的提言

第16章お問い合わせと免責事項